Compare THH & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | FEMY |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 11.5M |
| IPO Year | 2025 | 2021 |
| Metric | THH | FEMY |
|---|---|---|
| Price | $1.32 | $1.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 15.0K | ★ 102.5K |
| Earning Date | 11-21-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.45 |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.19 | $0.29 |
| 52 Week High | $56.26 | $6.29 |
| Indicator | THH | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 34.20 |
| Support Level | $0.27 | $0.33 |
| Resistance Level | $1.50 | $3.21 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 22.92 | 21.36 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.